We found that in tumor variants in which there is low intrinsic tumor level of PI3K/Akt/mTOR relative to that found in the stroma, blockage of pS6 activation through the use of PI3K/mTOR inhibitors interferes with MFP-induced neovascularization, immune cell infiltration and tumor regression. The gene discussed is AKT1; the disease is neoplasm.